CD274 and non-small cell lung carcinoma: The results demonstrated that, compared with chemotherapy, pembrolizumab monotherapy significantly prolonged OS in patients with locally advanced (stage III) or metastatic NSCLC, with the greatest treatment effect seen in PD-L1-high patients (PD-L1 ≥ 50%: 20.0 vs. 12.2 months; HR, 0.68; 95% CI, 0.57–0.82; PD-L1 ≥ 20%: 18.0 vs. 13.0 months; HR, 0.75; 95% CI, 0.64–0.88; PD-L1 ≥ 1%: 16.4 vs. 12.1 months; HR, 0.80; 95% CI, 0.71–0.90) (34, 35).